Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALNY Alnylam Pharmaceuticals

Pre-Market Trading 05-10 07:16:56 EDT

151.37

-0.92

-0.60%

High153.00	Low150.37	Vol329.25K
Open153.00	D1 Closing152.29	Amplitude1.73%
Mkt Cap19.15B	Tradable Cap19.07B	Total Shares126.49M
T/O49.90M	T/O Rate0.26%	Tradable Shares125.95M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ALNY","market":"US","secType":"STK","nameCN":"Alnylam Pharmaceuticals","latestPrice":151.37,"timestamp":1715284800000,"preClose":152.29,"halted":0,"volume":329246,"delay":0,"floatShares":125953897,"shares":126491778,"eps":-2.647864,"marketStatus":"Pre-Market Trading","change":-0.92,"latestTime":"05-10 07:16:56 EDT","open":153,"high":153,"low":150.37,"amount":49897810.77296,"amplitude":0.01727,"askPrice":156,"askSize":157,"bidPrice":141,"bidSize":3,"shortable":3,"etf":0,"ttmEps":-2.647864,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1715347800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":151.37,"postHourTrading":{"tag":"盘后","latestPrice":151.37,"preClose":151.37,"latestTime":"16:51 EDT","volume":14892,"amount":2254206.9,"timestamp":1715287911243},"volumeRatio":0.7456275237557016},"requestUrl":"/m/hq/s/ALNY","defaultTab":"news","newsList":[{"id":"2434302542","title":"Incyte Corp. Stock Outperforms Competitors Despite Losses On The Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2434302542","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2434302542?lang=en_us&edition=fundamental","pubTime":"2024-05-10 05:20","pubTimestamp":1715289600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Incyte Corp.  slipped 0.02% to $53.50 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index  rising 0.51% to 5,214.08 and the Dow Jones Industrial Average  rising 0.85% to 39,387.76.This was the stock's second consecutive day of losses.Incyte Corp. closed $13.87 below its 52-week high , which the company reached on January 4th.Despite its losses, the stock outperformed some of its competitors Thursday, as Alnylam Pharmaceuticals Inc.  fell 0.60% to $151.37.Trading volume  remained 496,993 below its 50-day average volume of 1.9 M.Data source: Dow Jones Market Data, FactSet. Data compiled May 9, 2024.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2433340274","title":"Alnylam Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2433340274","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2433340274?lang=en_us&edition=fundamental","pubTime":"2024-05-07 19:14","pubTimestamp":1715080440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 07, 2024 07:14 ET (11:14 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2432184576","title":"Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2432184576","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2432184576?lang=en_us&edition=fundamental","pubTime":"2024-05-04 00:29","pubTimestamp":1714753740,"startTime":"0","endTime":"0","summary":"The adjusted figure excluded items like stock-based compensation expenses and realized and unrealized  loss on marketable equity securities.Alnylam recorded total revenues of $494 million in the quarter, which surpassed the Zacks Consensus Estimate of $421 million. In the year-ago quarter, total revenues were $319 million. Net product revenues were $365 million, up 32% year over year on a reported basis, as well as at constant exchange rate, driven by increased patient numbers for Givlaari , Oxlumo  and the newly approved Amvuttra .Net revenues from collaborators were $119 million, up 225% from $36 million reported in the year-ago quarter. The uptick was primarily driven by revenues recognized under the company’s licensing agreement with Roche RHHBY, which included a $65 million milestone payment that Alnylam received upon dosing the first patient in the zilebesiran KARDIA-3 clinical study for hypertension indication.Year to date, shares of Alnylam have plunged 21.5% compared with thei","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/huDYWWooSs3LEZkYeanM9w--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c9aff063e0b66455eb97289290f920eb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/huDYWWooSs3LEZkYeanM9w--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c9aff063e0b66455eb97289290f920eb"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-alny-q1-loss-narrower-162900353.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432037699","title":"Alnylam Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2432037699","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2432037699?lang=en_us&edition=fundamental","pubTime":"2024-05-03 21:21","pubTimestamp":1714742509,"startTime":"0","endTime":"0","summary":"NasdaqGS:ALNY Earnings and Revenue Growth May 3rd 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 14%. Earnings per share  also surpassed analyst estimates by 55%.Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.The company's shares are up 4.6% from a week ago.You should learn about the   2 warning signs  we've spotted with Alnylam Pharmaceuticals .","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-pharmaceuticals-first-quarter-2024-132149217.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432421946","title":"Alnylam Pharmaceuticals Inc (ALNY) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2432421946","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2432421946?lang=en_us&edition=fundamental","pubTime":"2024-05-03 15:11","pubTimestamp":1714720315,"startTime":"0","endTime":"0","summary":"Total Product Revenues: $365 million, 32% growth year-over-year.TTR Franchise Revenue: $264 million, 29% growth year-over-year.Rare Franchise Revenue: $101 million, 40% growth year-over-year.Net Revenue from Collaborations: $119 million, 225% increase year-over-year.Gross Margin on Product Sales: Consistent at 85%.Non-GAAP Operating Gain: $2 million, significant improvement from Q1 2023.Cash, Cash Equivalents, and Marketable Securities: $2.4 billion, stable from end of 2023.2024 Revenue Guidance: Anticipated combined net product revenues between $1.4 billion and $1.5 billion.2024 Collaboration and Royalty Revenue Guidance: Range of $325 million to $425 million.2024 Combined Non-GAAP R&D and SG&A Expenses Guidance: Between $1.675 billion and $1.775 billion.GuruFocus has detected 3 Warning Signs with ALNY.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Alnylam Pharmaceuticals Inc  reported a robust 32% year-over-year growth in product r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-pharmaceuticals-inc-alny-q1-071155965.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432934698","title":"Alnylam Pharmaceuticals Price Target Maintained With a $200.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2432934698","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2432934698?lang=en_us&edition=fundamental","pubTime":"2024-05-03 02:51","pubTimestamp":1714675860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 02, 2024 14:51 ET (18:51 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2432413935","title":"Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Zimmer Biomet Holdings (ZBH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2432413935","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2432413935?lang=en_us&edition=fundamental","pubTime":"2024-05-03 01:40","pubTimestamp":1714671623,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY – Research Report) and Zimmer Biomet Holding...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-and-zimmer-biomet-holdings-zbh?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-and-zimmer-biomet-holdings-zbh?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2432989238","title":"Alnylam Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2432989238","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432989238?lang=en_us&edition=fundamental","pubTime":"2024-05-02 23:36","pubTimestamp":1714664168,"startTime":"0","endTime":"0","summary":"The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2024 Q1 earnings call.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4688528-alnylam-pharmaceuticals-inc-2024-q1-results-earnings-call-presentation","is_publish_highlight":false,"gpt_icon":0},{"id":"2432989474","title":"Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics","url":"https://stock-news.laohu8.com/highlight/detail?id=2432989474","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2432989474?lang=en_us&edition=fundamental","pubTime":"2024-05-02 22:00","pubTimestamp":1714658415,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals  reported $494.33 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 54.8%. EPS of -$0.16 for the same period compares to -$1.40 a year ago.The reported revenue represents a surprise of +17.39% over the Zacks Consensus Estimate of $421.1 million. With the consensus EPS estimate being -$0.75, the EPS surprise was +78.67%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Alnylam performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CorpxfcSD3xaruoFanouDg--~B/aD00NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CorpxfcSD3xaruoFanouDg--~B/aD00NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/compared-estimates-alnylam-alny-q1-140015629.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432094096","title":"Alnylam Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2432094096","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432094096?lang=en_us&edition=fundamental","pubTime":"2024-05-02 21:33","pubTimestamp":1714656788,"startTime":"0","endTime":"0","summary":"* Alnylam Pharmaceuticals Inc    reported a quarterly adjusted loss of 52 cents per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of $-1.4","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432598338","title":"Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2432598338","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2432598338?lang=en_us&edition=fundamental","pubTime":"2024-05-02 21:10","pubTimestamp":1714655404,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals  came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $1.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 78.67%. A quarter ago, it was expected that this RNA interference drug developer would post a loss of $1.20 per share when it actually produced a loss of $1.10, delivering a surprise of 8.33%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Alnylam , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $494.33 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 17.39%. This compares to year-ago revenues of $319.29 million. The company has topped consensus revenue estimates two times over the last four quarters.Investors should be mindful of the fact that the outlook for the industry can ha","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-pharmaceuticals-alny-reports-q1-131004447.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432672435","title":"Alnylam Pharmaceuticals Q1 EPS $(0.16), Sales $494.33M Beat $427.33M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2432672435","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2432672435?lang=en_us&edition=fundamental","pubTime":"2024-05-02 20:02","pubTimestamp":1714651368,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals Q1 EPS $(0.16), Sales $494.33M Beat $427.33M Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38580293/alnylam-pharmaceuticals-q1-eps-0-16-sales-494-33m-beat-427-33m-estimate","is_publish_highlight":false,"gpt_icon":0},{"id":"2432672988","title":"Alnylam Pharmaceuticals Non-GAAP EPS of -$0.16 beats by $0.32, revenue of $494.3M beats by $67.44M","url":"https://stock-news.laohu8.com/highlight/detail?id=2432672988","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432672988?lang=en_us&edition=fundamental","pubTime":"2024-05-02 20:02","pubTimestamp":1714651326,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals press release : Q1 Non-GAAP EPS of -$0.16  beats by $0.32. Revenue of $494.3M   beats by $67.44M.  Full year 2024 financial guidance is reiterated as follows:   Combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO1  $1,400 million - $1,500 million   Net Product Revenue Growth vs. 2023 at reported FX rates  13% to 21%   Net Product Revenue Growth vs. 2023 at CER  13% to 21%   Net revenues from collaborations and royalties  $325 million - $425 million   GAAP R&D and SG&A expenses  $1,900 million - $2,050 million   Non-GAAP R&D and SG&A expenses  $1,675 million - $1,775 million","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4098432-alnylam-pharmaceuticals-non-gaap-eps-of-0_16-beats-0_32-revenue-of-494_3m-beats-67_44m","is_publish_highlight":false,"gpt_icon":0},{"id":"2432672604","title":"BRIEF-Alnylam Pharmaceuticals Q1 Adjusted EPS USD -0.16 Vs. IBES Estimate USD -1.18","url":"https://stock-news.laohu8.com/highlight/detail?id=2432672604","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432672604?lang=en_us&edition=fundamental","pubTime":"2024-05-02 20:00","pubTimestamp":1714651246,"startTime":"0","endTime":"0","summary":"May 02 (Reuters) - Alnylam Pharmaceuticals Q1 basic EPS USD -0.52. * Q1 operating income USD -43.435 million * Q1 adjusted net income USD -20.666 million vs. IBES estimate USD -143.2 million * Q1 net income USD -65.935 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432160316","title":"Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity","url":"https://stock-news.laohu8.com/highlight/detail?id=2432160316","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2432160316?lang=en_us&edition=fundamental","pubTime":"2024-05-02 20:00","pubTimestamp":1714651200,"startTime":"0","endTime":"0","summary":"Achieved First Quarter 2024 Global Net Product Revenues of $365 Million, Representing 32% Year-Over-Year Growth Compared to Q1 2023, Including Continued Momentum from Total TTR Delivering 29% Year-Over-Year Growth –。Demonstrated Strong Progress with Zilebesiran Hypertension Program with Positive Results from KARDIA-2 Phase 2 Study and Initiation of KARDIA-3 Phase 2 Study –。Remain on Track to Report Topline Results from HELIOS-B Phase 3 Study of Vutrisiran in Late June or Early July –。Reiterated 2024 Financial Guidance, Including Combined Net Product Revenues of $1,400 Million to $1,500 Million –。CAMBRIDGE, Mass., May 02, 2024----Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2024 and reviewed recent business highlights.First Quarter 2024 and Recent Significant Corporate Highlights","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/urc24aIf2.e_eMzes7E_ZA--~B/aD00NDA7dz0xNTUyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/9e88135ff1a8b677b66dc633d54b813c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/urc24aIf2.e_eMzes7E_ZA--~B/aD00NDA7dz0xNTUyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/9e88135ff1a8b677b66dc633d54b813c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-pharmaceuticals-reports-first-quarter-120000022.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432650205","title":"Alnylam Pharmaceuticals Q1 2024 Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2432650205","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432650205?lang=en_us&edition=fundamental","pubTime":"2024-05-01 23:40","pubTimestamp":1714578008,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals  is scheduled to announce Q1 earnings results on Thursday, May 2nd, before market open. The consensus EPS Estimate is -$0.48  and the consensus Revenue Estimate is $426.86M . Over the last 2 years, ALNY has beaten EPS estimates 38% of the time and has beaten revenue estimates 38% of the time.  Over the last 3 months, EPS estimates have seen 5 upward revisions and 0 downward. Revenue estimates have seen 11 upward revisions and 0 downward.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4097457-alnylam-pharmaceuticals-q1-2024-earnings-preview","is_publish_highlight":false,"gpt_icon":0},{"id":"2432537715","title":"Alnylam Pharmaceuticals Inc    expected to post a loss of $1.18 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2432537715","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432537715?lang=en_us&edition=fundamental","pubTime":"2024-05-01 00:23","pubTimestamp":1714494223,"startTime":"0","endTime":"0","summary":"* Alnylam Pharmaceuticals Inc     is expected to show a rise in quarterly revenue when it reports  results on May 2 for the period ending March 31 2024   * The Cambridge Massachusetts-based  company i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alnylam.com","stockEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":-0.0291},{"period":"3month","weight":-0.1097},{"period":"6month","weight":-0.065},{"period":"1year","weight":-0.2825},{"period":"ytd","weight":-0.2092}],"compareEarnings":[{"period":"1week","weight":0.03},{"period":"1month","weight":0.0016},{"period":"3month","weight":0.0378},{"period":"6month","weight":0.1806},{"period":"1year","weight":0.2599},{"period":"ytd","weight":0.0944}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.031314},{"month":2,"riseRate":0.5,"avgChangeRate":0.008316},{"month":3,"riseRate":0.45,"avgChangeRate":-0.018527},{"month":4,"riseRate":0.4,"avgChangeRate":-0.019432},{"month":5,"riseRate":0.6,"avgChangeRate":0.036475},{"month":6,"riseRate":0.6,"avgChangeRate":0.035552},{"month":7,"riseRate":0.7,"avgChangeRate":0.108614},{"month":8,"riseRate":0.55,"avgChangeRate":0.028475},{"month":9,"riseRate":0.5,"avgChangeRate":0.034438},{"month":10,"riseRate":0.4,"avgChangeRate":-0.044685},{"month":11,"riseRate":0.8,"avgChangeRate":0.089497},{"month":12,"riseRate":0.5,"avgChangeRate":0.016329}],"exchange":"NASDAQ","name":"Alnylam Pharmaceuticals","nameEN":"Alnylam Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alnylam Pharmaceuticals,ALNY,Alnylam Pharmaceuticals股票,Alnylam Pharmaceuticals股票老虎,Alnylam Pharmaceuticals股票老虎国际,Alnylam Pharmaceuticals行情,Alnylam Pharmaceuticals股票行情,Alnylam Pharmaceuticals股价,Alnylam Pharmaceuticals股市,Alnylam Pharmaceuticals股票价格,Alnylam Pharmaceuticals股票交易,Alnylam Pharmaceuticals股票购买,Alnylam Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction